Clinical Trials Logo
  1. Home
  2. Alcohol Dependence
  3. NCT01382316
  4. Details
NCT01382316 Clinical Trial

Making Alcoholics Anonymous Easier

Alcohol Dependence Clinical Trial

— MAAEZ  

Official title:
Making Alcoholics Anonymous Easier: A Group TSF Approach

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01382316
Other study ID # R01AA014688
Secondary ID
Status Completed
Phase Phase 3
First received June 24, 2011
Last updated June 24, 2011
Start date July 2005
Est. completion date August 2007

Study information
Verified date June 2011
Source Alcohol Research Group
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This study tests the effectiveness of Making Alcoholics Anonymous Easier (MAAEZ), a manual-guided intervention designed to help alcohol and drug dependent clients connect with individuals encountered in AA. An OFF/ON design was used (n=508). MAAEZ effectiveness was determined by comparing abstinence rates of participants recruited during ON (MAAEZ intervention) and OFF (usual care) conditions and by studying the effect of the number of MAAEZ sessions attended. Better outcomes were hypothesized for MAAEZ vs. usual care. At 12 months, more clients in the ON condition (vs. OFF) reported past 30-day abstinence from alcohol, drugs, and both alcohol and drugs. Abstinence increased for each additional MAAEZ session received. MAAEZ appeared especially effective for those with more prior AA exposure, severe psychiatric problems, and atheists/agnostics. Mechanisms of action for MAAEZ (mediators of the MAAEZ effect) include: doing service in AA/NA/CA; having a sponsor; having a social network supportive of abstinence; and comfort being in meetings. MAAEZ represents an evidence-based intervention that is easily implemented in existing treatment programs.

Other known NCT identifiers
  • NCT01244919

Recruitment information / eligibility
Status Completed
Enrollment 508
Est. completion date August 2007
Est. primary completion date May 2006
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- current alcohol or drug dependence diagnosis

Exclusion Criteria:

- incapacitating mental or physical health; under age 18

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Behavioral:
• Making Alcoholics Anonymous Easier (MAAEZ)
6-week, 90-minute, manualized, 12-step facilitation intervention consisting of 6 weekly session. First session is introduction. Four following core sessions attended in any order: sponsorship, principles not personalities, spirituality, living Sober. Last session, return to intro session as graduate.
• Usual care
Group format, six weekly education sessions about alcohol and drugs

Locations
Country Name City State
United States Alcohol Research Group Emeryville California

Sponsors (1)
Lead Sponsor Collaborator
Alcohol Research Group

Country where clinical trial is conducted

United States, 

References & Publications (3)

Kaskutas LA, Subbaraman MS, Witbrodt J, Zemore SE. Effectiveness of Making Alcoholics Anonymous Easier: a group format 12-step facilitation approach. J Subst Abuse Treat. 2009 Oct;37(3):228-39. doi: 10.1016/j.jsat.2009.01.004. Epub 2009 Apr 1. Erratum in: J Subst Abuse Treat. 2013 Oct;45(4):388. — View Citation

Subbaraman MS, Kaskutas LA, Zemore S. Sponsorship and service as mediators of the effects of Making Alcoholics Anonymous Easier (MAAEZ), a 12-step facilitation intervention. Drug Alcohol Depend. 2011 Jul 1;116(1-3):117-24. doi: 10.1016/j.drugalcdep.2010.12.008. Epub 2011 Feb 2. — View Citation

Zemore SE, Kaskutas LA. Development and validation of the Alcoholics Anonymous Intention Measure (AAIM). Drug Alcohol Depend. 2009 Oct 1;104(3):204-11. doi: 10.1016/j.drugalcdep.2009.04.019. Epub 2009 Jul 5. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Alcohol and drug abstinence No alcohol and no drug consumed during the 30 days prior to 12-month follow-up interview Past 30 days No
See also
  Status Clinical Trial Phase
Completed NCT03340051 - Remote Alcohol Monitoring and Episodic Thinking N/A
Completed NCT02901041 - Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism Phase 3
Not yet recruiting NCT06444243 - Psilocybin-assisted Therapy for Alcohol Use Disorder Phase 2
Completed NCT02486900 - Neurofeedback & Alcohol Dependence N/A
Completed NCT02705898 - Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women N/A
Completed NCT02179749 - Mifepristone Treatment of Alcohol Use Disorder Phase 2
Completed NCT02197598 - Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use Phase 4
Recruiting NCT02385643 - The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients N/A
Completed NCT01828866 - Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients N/A
Terminated NCT01408641 - Topiramate for Alcohol Use in Posttraumatic Stress Disorder N/A
Active, not recruiting NCT01182766 - New Treatment for Alcohol and Nicotine Dependence Phase 2/Phase 3
Completed NCT02193204 - Chronic Alcohol, Stress Inflammatory Response and Relapse Risk N/A
Completed NCT01342549 - Treatment Strategy for Alcohol Use Disorders in Veterans With TBI Phase 3
Completed NCT01165541 - A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency Phase 2
Completed NCT01176591 - HBPL Study of the Impact of the NK1 Antagonist Aprepitant Phase 2
Completed NCT00585780 - Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse Phase 1/Phase 2
Completed NCT01056484 - Mindfulness Meditation for Health Phase 2
Completed NCT00607620 - Disseminating Organizational SBI Services at Trauma Centers N/A
Completed NCT00884884 - Aripiprazole and Topiramate on Free-Choice Alcohol Use Phase 2/Phase 3
Completed NCT00463346 - Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism Phase 3

External Links